This is a working overview of dual agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-14. Anything still debated is marked as such rather than presented as settled.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Cold-chain handling is standard for formulated product, with dry powder stored frozen and ready-to-use solutions refrigerated. Light exposure is minimized because photodegradation of certain amino acid side chains is possible. Shipping and temperature-excursion studies are used to establish whether short deviations affect quality attributes. Documentation supplied with research material usually includes a certificate of analysis listing purity, identity confirmation, and water or residual solvent content. Users are expected to confirm that material meets the stated specification before use.
Identity and purity of tirzepatide are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Because the molecule carries several modifications, gradient conditions are adjusted to resolve the intact peptide from deamidation and oxidation products. Enzymatic digestion followed by peptide mapping confirms the primary sequence and locates specific modifications. Quantitation in biological matrices typically uses liquid chromatography with tandem mass spectrometry after solid-phase extraction. Immunoassays are used less often, since antibody cross-reactivity with closely related peptides can bias results.
The peptide shares degradation routes common to modified peptides: deamidation of asparagine and glutamine residues, oxidation of methionine, and backbone hydrolysis under extreme pH. Lyophilized material is generally more stable than a solution, and residual water content directly affects the rate of hydrolysis. In liquid form, aggregation and visible particles can appear after agitation or repeated freeze-thaw cycles. Stability studies therefore track monomer content, aggregate content, and potency over months under defined temperature and humidity.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Unmodified peptide backbone |
| Molecular mass | approx. 4,813 Da | 39-residue linear chain |
| Receptor targets | GIP and GLP-1 | Dual agonist activity |
| Route | Subcutaneous injection | Weekly administration interval |
| Elimination half-life | approx. 5 days | Supports weekly dosing schedule |
Regulatory and quality discussions place the peptide within established guidance for synthetic peptides and biologics. Forced degradation studies, in which samples are exposed to heat, acid, base, peroxide, and light, identify likely degradation products and validate the selectivity of analytical methods. Reference standards allow comparison across laboratories and production batches. Purity specifications reported in the literature usually combine chromatographic purity with mass confirmation. Which impurity thresholds are meaningful for long-term behavior is still debated, and no single universal specification has been adopted across all jurisdictions.
Routine characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity assessment, usually with ultraviolet detection near 214 nanometers. Intact mass measurement by liquid chromatography coupled to mass spectrometry confirms molecular identity against a theoretical value. Sequence-level confirmation uses enzymatic digestion followed by tandem mass spectrometry, an approach known as peptide mapping. Amino acid analysis gives an independent check on composition. Circular dichroism spectra are used to estimate helical content in aqueous buffer.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Mycosporine-like amino acids (MAAs) are small secondary metabolites produced by organisms that live in environments with high volumes of sunlight, usually marine environments. The exact number of compounds within this class of natural products is yet to be determined, since they have only relatively recently been discovered and novel molecular species are constantly being discovered; however, to date their number is around 30. They are commonly described as "microbial sunscreens" although their function is believed not to be limited to sun protection. MAAs represent high potential in cosmetics, and biotechnological applications. Indeed, their UV-absorbing properties would allow to create products derived from natural photoprotectors, potentially harmless to the environment and efficient against UV damage.
=== Solubility === As an example of the wide range of solubility of calcium compounds, monocalcium phosphate is very soluble in water, 85% of extracellular calcium is as dicalcium phosphate with a solubility of 2.00 mM, and the hydroxyapatite of bones in an organic matrix is tricalcium phosphate with a solubility of 1000 μM.
The first whole genome sequencing study to comprehensively catalog de novo structural variation at a much higher resolution than DNA microarray studies has shown that the mutation rate is approximately 20% and not elevated in autism compared to sibling controls. Structural variants in individuals with autism are much larger and four times more likely to disrupt genes, mirroring findings from CNV studies. CNV studies were closely followed by exome sequencing studies, which sequence the 1–2% of the genome that codes for proteins (the "exome"). These studies found that de novo gene inactivating mutations were observed in approximately 20% of individuals with autism, compared to 10% of unaffected siblings, suggesting the etiology of autism is driven by these mutations in around 10% of cases. There are predicted to be 350-450 genes that significantly increase susceptibility to autism when impacted by inactivating de novo mutations. A further 12% of cases are predicted to be caused by protein altering missense mutations that change an amino acid but do not inactivate a gene. Therefore, approximately 30% of individuals with autism have a spontaneous de novo large CNV that deletes or duplicates genes, or mutation that changes the amino acid code of an individual gene. A further 5–10% of cases have inherited structural variation at loci known to be associated with autism, and these known structural variants may arise de novo in the parents of affected children.
Montgomery launched his major assault on the Mareth Line, Operation Pugilist, on 16 March. The Rhodesian Anti-Tank Battery, operating with the 50th (Northumbrian) Infantry Division, took part. The Allies advanced at first but the weather and terrain prevented the tanks and guns from moving forward, allowing the 15th Panzer Division to counter-attack successfully. A flanking movement by the 2nd New Zealand Division around the right of the German forces, through the Tebaga Gap, compelled an Axis withdrawal on 27 March. The Rhodesian anti-tank gunners fought their last action in Africa at Enfidaville, 50 kilometres (31 mi) south of Tunis, on 20 April. The KRRC Rhodesians meanwhile took part in a long outflanking march which brought them to El Arousse, 65 kilometres (40 mi) south-west of Tunis, the next day. British armour entered Tunis on 7 May 1943. The Axis forces in North Africa—over 220,000 Germans and Italians, including 26 generals—surrendered a week later. By time Tunis had fallen, few Rhodesians remained with the First or Eighth Armies; most were transferring to the South African 6th Armoured Division, then in Egypt, or making their way home on leave. Out of the 300 Southern Rhodesians who had joined the KRRC in Egypt, only three officers and 109 other ranks remained at the end of the Tunisian Campaign. The Rhodesian Anti-Tank Battery retraced many of the movements it had taken during the campaign as it returned to Egypt. "Left for Matruh at 0830 hours today," one Rhodesian gunner wrote. "Camped at night on the identical spot where we camped in June 1941.
Moreover, mining hardware's short lifespan results in electronic waste. In October 2025, the US was the largest mining country with 38% of the global bitcoin mining market share, followed by Russia (16%) and China (14%, despite all cryptocurrency trading and mining being banned there in 2021).
Sources: en.wikipedia.org
== Career == Bigbie attended Ball State University. In 1998, he played collegiate summer baseball with the Wareham Gatemen of the Cape Cod Baseball League. Bigbie was drafted by the Baltimore Orioles in the 1st round (21st pick overall) of the 1999 Major League Baseball amateur draft and played over four years (2001–2005) for the Orioles before being traded during the 2005 season to the Colorado Rockies. Bigbie played the remainder of 2005 season for the Rockies. On December 8, 2005, the Rockies traded him and Aaron Miles to the St. Louis Cardinals for pitcher Ray King. On February 2, 2007, he signed a minor league deal with the Los Angeles Dodgers. Bigbie exercised a free agent option in his contract on June 1, 2007, and on June 11 signed a minor league contract with the Braves. During his six-year career, he posted a .268 batting average, hitting 31 home runs and amassing 322 hits in 375 games. Bigbie is an average fielder, but has an above-average arm. He batted .240 in 2006 with the Cardinals, also posting only 1 RBI, in 17 games. In December 2007, it was announced that he had agreed to a deal to play for the Yokohama Bay Stars of the Nippon Professional Baseball (NPB). Bigbie made a comeback for the 2010 season, playing for the Edmonton Capitals of the Golden Baseball League. Bigbie was named the DH for Baseball America's 2010 All-Independent Leagues Team.
However, in spent nuclear fuel that does not quickly undergo nuclear reprocessing but instead is cooled for years after use, much or most of the 241Pu will beta decay to americium-241, one of the minor actinides, a strong alpha emitter, and difficult to use in thermal reactors. 242Pu has a particularly low cross section for thermal neutron capture; and it takes three neutron absorptions to become another fissile isotope (either curium-245 or 241Pu) and fission. Even then, there is a chance either of those two fissile isotopes will fail to fission but instead absorb a fourth neutron, becoming curium-246 (on the way to even heavier actinides like californium, which is a neutron emitter by spontaneous fission and difficult to handle) or becoming 242Pu again; so the mean number of neutrons absorbed before fission is even higher than 3. Therefore, 242Pu is particularly unsuited to recycling in a thermal reactor and would be better used in a fast reactor where it can be fissioned directly. However, 242Pu's low cross section means that relatively little of it will be transmuted during one cycle in a thermal reactor. 242Pu's half-life is about 15 times as long as 239Pu's half-life; therefore, it is 1/15 as radioactive and not one of the larger contributors to nuclear waste radioactivity. 242Pu's gamma ray emissions are also weaker than those of the other isotopes. 243Pu has a half-life of only 5 hours, beta decaying to americium-243.
In 1987, Yates purchased Temple Gym on Temple Street in Birmingham. In 2006, he franchised four additional Temple Gym locations, three of which are in the UK. As of 2020, only the original Birmingham gym is still in operation; it later relocated from Temple Street to the city's Jewellery Quarter. In 1994, Yates and bodybuilding brothers Mike and Ray Mentzer formed the California-based company Heavy Duty Inc., which marketed athletic apparel and bodybuilding books. In 1998, he partnered with Kerry Kayes to form the bodybuilding supplement company CNP Professional, which marketed a "Dorian Yates Approved" product line in the U.S. He left the company in 2006 to form his own company, Dorian Yates Ultimate Formulas, which offers a line of protein and weight-gain supplements. Yates started a second company in 2010 called EU Peptides, which sells peptide hormones and other pro-hormone supplements. He left this company in 2012, having founded a third company called DY Nutrition in 2011; it specializes in pre-workout formulas, has released several training DVDs, and offers a line of workout related supplements endorsed by Yates.
=== 1. FC Lokomotive (1966–1990) === East German football went through a general reorganization in 1965, creating football clubs as centres of high-level football, during which the football department of SC Leipzig was separated from the sports club and reformed into football club 1. FC Lokomotive Leipzig, while rival Chemie Leipzig continued as a Betriebssportgemeinschaft (BSG), or corporate team. Like most East German clubs, it was assigned to a publicly owned enterprise as its "sponsor". In the case of Lokomotive, the providing enterprise was Deutsche Reichsbahn—the East German state railways—hence the name. The club's fortunes improved somewhat as they almost always finished well up the league table, but they were unable to win the top honour in the DDR-Oberliga, with losing final appearances in 1967, 1986, and 1988. Lok earned a clutch of East German Cups (FDGB Pokal) with victories in 1976, 1981, 1986, and 1987, against failed appearances in the Cup final in 1970, 1973, and 1977. They also won the UEFA Intertoto Cup in 1966 and made an appearance in the 1987 final of the European Cup Winners' Cup, falling 0–1 to Johan Cruyff's Ajax after a Marco van Basten goal.
=== Anthropogenic influences === Anthropogenic industry unintentionally injects micronutrients into various ecosystems across the globe. The addition of micronutrients into ecosystems can have both positive and negative impacts. In the face of climate change, the fertilization of oceans with iron has been proposed as a method of carbon sequestration; however, elevated levels of iron in high nutrient, low chlorophyll regions of the ocean can cause the production of harmful algal blooms which are toxic to both humans and marine life. Similarly, in lakes, isolated seas, and coastal bays or gulfs, addition of micronutrients can cause eutrophication leading to hypoxia, decreasing ecosystem health. Micronutrients are released into ecosystems from many anthropogenic activities. Fossil fuel combustion releases micronutrients such as Zn, Fe, Ni, and Cu into the atmosphere, surrounding soils, and nearby waterways. Agricultural fertilizer runoff contains many micronutrients like Fe, Mn, Zn, Cu, Co, B, Mo and Ni. Fertilizer runoff injects these micronutrients into groundwater, soils, and waterways. Deforestation decreases soil compaction, resulting in increased aeolian transport of dust containing micronutrients, especially Fe. Industrial mining produces tailings which contaminates runoff. The improper treatment of mining tailings can result in the leakage of micronutrients into groundwater, soils, and nearby waterways.
Sources: en.wikipedia.org
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.
Selective agents engage only the GLP-1 receptor, whereas tirzepatide activates GIP and GLP-1 receptors simultaneously. This difference in receptor coverage is the principal pharmacological distinction emphasised in comparative reviews.
Downstream signalling is partly characterised, but the quantitative contribution of GIP versus GLP-1 receptor activation to metabolic outcomes is not settled. Review articles commonly flag this as an unresolved question rather than a settled finding.
Reversed-phase liquid chromatography with ultraviolet detection is the usual approach, frequently combined with mass spectrometry for identity. Purity is reported as the area percentage of the main peak. Related impurities eluting near the main peak are usually summed and reported separately.